Contraception · Oral Contraceptives

Former long-term use of combined hormonal contraception and glucose metabolism disorders in perimenopausal women: A prospective, population-based cohort study

Mosorin ME, Ollila MM, Nordström T, Jokelainen J, Piltonen T, Auvinen J, Morin-Papunen L, Tapanainen J

Published November 2023 Acta Obstetricia Et Gynecologica Scandinavica, 102(11), 1488-1495
DOI 10.1111/aogs.14636 PMID 37568273 PMC PMC10577621

RRM Academy Synopsis

Past combined hormonal contraception over 10 years tied to prediabetes

Past combined hormonal contraceptive use for over 10 years was associated with prediabetes. Among 46-year-old women in a Finnish birth cohort, past users of over 10 years had 3.9 times the odds of prediabetes after adjustment. The comparison group had no hormonal contraception history. Newly found type 2 diabetes was not associated with over 10 years of past use.

Key Findings

  • After adjustment, women with over 10 years of past combined hormonal contraceptive use had 3.9 times the odds of prediabetes of women with no hormonal contraception history (95% CI 1.6–9.2).
  • Prediabetes occurred in 39 of 339 (11.5%) with over 10 years of past use and 19 of 253 (7.5%) with no history. The unadjusted odds ratio was 1.5 (95% CI 0.9–2.7).
  • For past use under 5 years the adjusted odds ratio for prediabetes was 1.7 (95% CI 0.8–3.9), and for 5 to 10 years it was 1.8 (95% CI 0.8–4.1).
  • Newly found type 2 diabetes was not associated with over 10 years of past use: 3 of 339 (0.9%) versus 9 of 253 (3.6%), adjusted odds ratio 0.5 (95% CI 0.1–2.9).
  • Past use of progestin-only contraceptives, in 52 women, was not associated with prediabetes or new type 2 diabetes.

Interpretation

This cohort study followed the Northern Finland Birth Cohort 1966, a group of women, from pregnancy to age 46. A questionnaire at age 46 gave the contraceptive history. An oral glucose tolerance test found the prediabetes. The women were 46 years old and Caucasian. The link held even after women who reported polycystic ovary syndrome (PCOS, now also called polyendocrine metabolic ovarian syndrome, PMOS) were left out. The authors note the progestin-only group was too small for firm conclusions. The findings support larger studies of long-term hormonal contraceptive use and glucose metabolism.

RRM Context

Combined hormonal contraceptives are suppressive medications. They hold back ovulation while taken. Restorative reproductive medicine looks for the cause of cycle and blood sugar problems together. The authors cite a Swedish study that found a two-fold increased risk of prediabetes in former users. The authors suggest the finding could point to a need for glucose screening in these women.

Abstract

Introduction

Current use of combined hormonal contraceptives worsens glucose tolerance and increases the risk of type 2 diabetes mellitus at late fertile age, but the impact of their former use on the risk of glucose metabolism disorders is still controversial.

Materials and Methods

This was a prospective, longitudinal birth cohort study with long-term follow-up consisting of 5889 women. The cohort population has been followed at birth, and at ages of 1, 14, 31 and 46. In total, 3280 (55.7%) women were clinically examined and 2780 also underwent a 2-h oral glucose tolerance test at age 46. Glucose metabolism indices were analyzed in former combined hormonal contraceptive users (n = 1371) and former progestin-only contraceptive users (n = 52) and in women with no history of hormonal contraceptive use (n = 253).

Results

Compared with women with no history of hormonal contraceptive use, those who formerly used combined hormonal contraceptives for over 10 years had an increased risk of prediabetes (odds ratio [OR] 3.9, 95% confidence interval [CI]: 1.6-9.2) but not of type 2 diabetes mellitus. Former progestin-only contraceptive use was not associated with any glucose metabolism disorders. The results persisted after adjusting for socioeconomic status, smoking, alcohol consumption, parity, body mass index and use of cholesterol-lowering medication.

Conclusions

Former long-term use of combined hormonal contraceptives was associated with a significantly increased risk of prediabetes in perimenopausal women, which potentially indicates a need of screening for glucose metabolism disorders in these women.

Topics

By this author

Related research

Contraception › Oral Contraceptives › Metabolic Effects · Therapeutics › Hormonal Agents › Estrogen Preparations
Maria-Elina Mosorin, Meri-Maija Ollila, Tanja Nordström, Jari Jokelainen, Terhi Piltonen, Juha Auvinen, Laure Morin-Papunen, Juha Tapanainen
M Mosorin, M Ollila, T Nordström, J Jokelainen, T Piltonen, J Auvinen, L Morin-Papunen, J Tapanainen
PMID 37568273 37568273 DOI 10.1111/aogs.14636 10.1111/aogs.14636 Mosorin et al. 2023, Mosorin 2023